uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewsWire • 06/25/26
QURE Announces Initial Data on Gene therapy for Temporal Lobe EpilepsyZacks Investment Research • 06/22/26
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe EpilepsyGlobeNewsWire • 06/19/26
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An EndInvestors Business Daily • 06/17/26
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agencyCNBC • 06/17/26
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's DiseaseGlobeNewsWire • 06/17/26
UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In PlaySeeking Alpha • 05/12/26
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company UpdatesGlobeNewsWire • 05/05/26